[{"from": "human", "value": "What can you tell me about this molecule? [C][=C][N][Branch1][#Branch2][C][=Branch1][C][=O][N][=C][Ring1][#Branch1][N][C@H1][C@@H1][Branch1][=C][C@@H1][Branch1][#Branch2][C][=Branch1][Branch1][=C][Ring1][Branch1][F][C][O][O][O]"}, {"from": "gpt", "value": "The molecule is an orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, tRoducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway."}]